Anika Therapeutics Inc (ANIK) posted 10% revenue growth and record commercial channel sales in Q3 2026, but lowered commercial guidance and faces FDA setbacks on its Hyalafast PMA.
Motley Fool Press Release.
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Detailed price information for Anika Therapeutics (ANIK-Q) from The Globe and Mail including charting and trades.
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
This is the newest page. Registered accounts read further back.